Alternating or Combined Therapy With Axitinib and Bosutinib for Patients With Chronic Myeloid Leukemia in Chronic, Accelerated or Blastic Phases
Phase of Trial: Phase I/II
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Axitinib (Primary) ; Bosutinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 20 Mar 2017 Planned End Date changed from 1 May 2021 to 1 Mar 2021.
- 20 Mar 2017 Planned primary completion date changed from 1 May 2021 to 1 Mar 2021.